TransMedics (TMDX) EBIT (2018 - 2026)

TransMedics has reported EBIT for 9 years, with the latest figure at $23.7 million in Q2 2026.

• On a quarterly basis, EBIT fell 35.09% year-over-year to $23.7 million in Q2 2026; TTM through Jun 2026 was $81.6 million, a 6.57% increase from a year earlier, with the FY2025 full-year figure at $108.6 million, up 189.59% from the prior year.
• EBIT was $23.7 million for Q2 2026 at TransMedics, up from $13.3 million in the prior quarter.
• The five-year high for EBIT was $36.6 million in Q2 2025, with the low at -$28.3 million in Q3 2023.
• Average EBIT over 5 years is $6.8 million, with a median of $6.3 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: EBIT plunged 411.09% in 2023, then surged 1480.57% in 2024.
• Over 5 years, EBIT stood at -$6.8 million in 2022, then jumped by 138.4% to $2.6 million in 2023, then jumped by 232.08% to $8.6 million in 2024, then jumped by 146.1% to $21.3 million in 2025, then gained by 11.58% to $23.7 million in 2026.
• The last three EBIT figures came in at $23.7 million (Q2 2026), $13.3 million (Q1 2026), and $21.3 million (Q4 2025), per Business Quant data.